The Pennsylvania State University College of Medicine
Hershey, Pennsylvania, 17033, United States
NCT Number: NCT03625986
The overall goal of this project is to understand the likely health effects of cigarette smokers switching to a Standardized Research Electronic Cigarette (SREC) and to assess the role of nicotine delivery on switching and acceptability as well as markers of health outcomes.
Current smokers who meet all eligibility criteria will completely switch from their combustible (regular) cigarettes to an electronic cigarette (SREC) that either contains 58 mg/ml of nicotine or 0 mg/ml of nicotine in the liquid.
The investigators' hypothesis is that attempting to switch to a SREC will result in a reduction in markers of harms to health, as compared with the baseline (smoking) measures. The investigators also hypothesize that nicotine-containing SRECs will facilitate switching from smoking more efficiently than zero nicotine SRECs and will result in a significantly greater improvement in markers of health risk, but will result in higher ratings of dependence on the SREC (as compared to the zero nicotine SREC).
Looking for future studies?
Notify Me21 year–70 year
All sexes
Interventional
Not applicable
Hershey, Pennsylvania, 17033, United States
This project is a prospective parallel-group randomized double-blind, placebo-controlled study in which 104 current smokers who are willing to completely switch from their regular cigarettes to an electronic cigarette (SREC) for 6 weeks will be randomly allocated to use a SREC containing either 58 or 0 mg/ml nicotine in the liquid.
Following randomization to their assigned study product, participants will be supported in their switching efforts with regular contacts both in person at the Penn State Milton S. Hershey Medical Center and over the phone. The main measures will be recorded at two in-person visits after the randomization (switching) visit: (a) 3 weeks after switching and (b) 6 weeks after switching. All participants will also be followed up at 10 weeks by phone to identify whether they have continued to use electronic cigarettes or regular cigarettes and to assess their motivation to change.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir ("pod") and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 58 mg/mL of nicotine.
Other names: 58 mg/mL Nicotine Content SREC
The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir ("pod") and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine.
Other names: 0 mg/mL Nicotine Content SREC
Time frame: 6-week visit (post-treatment)
Concentration of urinary carcinogen biomarker of exposure, NNAL, corrected for creatinine
Time frame: 6-week visit (post-treatment)
Forced expiratory volume in one second (FEV1).
Time frame: 6-week visit (post-treatment)
Exhaled CO (parts per million [ppm])
Time frame: 6-week visit (post-treatment)
Cotinine (ng/ml) will serve as a measure of exposure to nicotine.
Time frame: 6-week visit (post-treatment)
systolic blood pressure in mm Hg
Time frame: 6-week visit (post-treatment)
Nicotine dependence for cigarettes will be assessed via the Fagerstrom Test for Nicotine Dependence (FTND), a measure with total scores ranging from 0 (very low dependence) to 10 (very high dependence).
Time frame: 6-week visit (post-treatment)
Nicotine dependence for e-cigarettes will be assessed via the Penn State Electronic Nicotine Dependence Index, a measure with total scores ranging from 0 (very low dependence) to 20 (very high dependence).
Time frame: 6-week visit (post-treatment)
Mean number of cigarettes smoked per day based on the past 7 days
Time frame: 6-week visit (post-treatment)
Zero cigarettes or other tobacco products (not including e-cigs) used in the past 7 days and a CO <6ppm
Time frame: 1-week visit (post-treatment)
Withdrawal and craving will be assessed via the Minnesota Nicotine Withdrawal Scale. Total scores range from 0-28. Higher scores indicate worse withdrawal symptoms.
Time frame: 10-week visit (post-treatment)
Mean number of cigarettes smoked per day based on the past 7 days
Time frame: 10-week visit (post-treatment)
The number of days the e-cig was used since 6-week visit (post-treatment)
Time frame: 10-week visit (post-treatment)
Abstinence will be considered zero cigarettes and other tobacco products (not including e-cigs) in the past 7 days
Time frame: 6-week visit (post-treatment)
Heart Rate Variability (HRV) will be assessed from resting Holter EKG output.
Time frame: 6-week visit (post-treatment)
Presence of PVCs will be assessed from resting Holter EKG output.
Time frame: 6-week visit (post-treatment)
ST-Elevation will be assessed from resting Holter EKG output
Time frame: 6-week visit (post-treatment)
QRS duration will be assessed from resting Holter EKG output.
Milton S. Hershey Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03905928
Behavior, Chemically-Induced Disorders
Hershey, Pennsylvania, United States
View Trial DetailsNCT03496077
Behavior, Chemically-Induced Disorders
Farmington, Connecticut, United States
View Trial DetailsNCT05836051
Behavior, Behavior, Addictive
Hershey, Pennsylvania, United States
View Trial DetailsNCT04188197
Behavior, Chemically-Induced Disorders
Charlotte, North Carolina, United States
View Trial Details